rituximab biosuperior (Xencor)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerituximab biosuperior (Xencor)

Drug Alias Namerituximab biobetter (Xencor)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesXencor Inc Genentech Inc

Active IndicationsN/A

Inactive IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A